Northern Trust Corp Increases Position in TransMedics Group, Inc. $TMDX

Northern Trust Corp lifted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 2.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 361,963 shares of the company’s stock after acquiring an additional 7,341 shares during the quarter. Northern Trust Corp owned 1.07% of TransMedics Group worth $24,353,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. NBC Securities Inc. purchased a new stake in shares of TransMedics Group during the first quarter worth about $25,000. Hager Investment Management Services LLC increased its holdings in TransMedics Group by 38.3% in the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company’s stock valued at $50,000 after buying an additional 205 shares during the last quarter. CWM LLC raised its stake in TransMedics Group by 20.1% during the first quarter. CWM LLC now owns 925 shares of the company’s stock valued at $62,000 after buying an additional 155 shares in the last quarter. GAMMA Investing LLC raised its stake in TransMedics Group by 551.7% during the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company’s stock valued at $105,000 after buying an additional 1,324 shares in the last quarter. Finally, Sava Infond d.o.o. raised its stake in TransMedics Group by 46.7% during the first quarter. Sava Infond d.o.o. now owns 2,200 shares of the company’s stock valued at $148,000 after buying an additional 700 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the transaction, the insider directly owned 13,955 shares of the company’s stock, valued at $1,950,909. This represents a 4.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.00% of the stock is owned by company insiders.

Analyst Ratings Changes

TMDX has been the subject of a number of research reports. Canaccord Genuity Group lifted their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a “buy” rating in a report on Tuesday, July 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Morgan Stanley lifted their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Wall Street Zen downgraded shares of TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Monday, August 25th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $123.00.

TransMedics Group Stock Down 1.5%

NASDAQ:TMDX opened at $114.96 on Monday. The firm has a market capitalization of $3.92 billion, a PE ratio of 59.57 and a beta of 2.18. The stock has a 50 day moving average of $120.24 and a 200-day moving average of $103.29. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $172.78. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The company had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. During the same period in the prior year, the company earned $0.35 earnings per share. The business’s revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. Analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.